ROS1 and lung carcinoma: The results show that SHP2 and c-Jun pathways regulate PD-L1 expression in ROS1 fusion crizotinib resistant lung cancer cells, indicating that distinct oncogene ROS1 possesses signaling pathways for the regulation of PD-L1 expression in NSCLCs.